BD 2014 financial report

Source: bidi medical devices (Shanghai) Co., Ltd 2014-11-06 BD recently published financial statements for 2014 In the full fiscal year ended September 30, 2014, the company's global revenue reached $8.446 billion, an increase of 4.9% over the previous year (5.2% in the case of exchange rate neutrality) In addition, the fourth quarter report released at the same time showed that global revenue in the fourth quarter was US $2.202 billion, up 4.8% year-on-year, and 4.6% in the case of exchange rate neutrality "The newly released financial report shows BD's excellent performance, which undoubtedly provides a satisfactory answer for 2014 financial year." Vince a forlenza, chairman, CEO and President of BD board, said, "while maintaining investment and supporting innovative enterprise strategy, our revenue can continue to grow organically and reach a healthy development level With such a strong growth base, we are confident in BD's performance in fy2015 " The strong financial performance comes from the pleasant growth of various business departments In fy2014, the global revenue of BD medical system increased by 6.2% (6.3% year-on-year growth in the case of exchange rate neutrality); the growth rate of BD diagnosis business was 2.5%, equivalent to 3.3% growth rate after exchange rate conversion; the annual growth rate of BD biological science business was 5.2, 5.5% after exchange rate conversion In fy2014, growth in emerging markets remained stable US domestic revenue was $3.417 billion, up 1.9% from fy2013 Revenue from markets outside the US was $5.029 billion, up 7% year-on-year (7.6% on exchange rate translation) After the early announcement of the acquisition of conersion, BD made a forecast for the performance of 2015 fiscal year Under the condition of exchange rate neutrality, the company expects to achieve a growth rate of 4.5% - 5.0% Considering the exchange rate fluctuation, the growth rate is expected to be 2.0% - 2.5%.